Antazoline

Identification

Name
Antazoline
Accession Number
DB08799
Description

Antazoline is a 1st generation antihistamine with anticholinergic activity. It is used to relieve nasal congestion. It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 265.3529
Monoisotopic: 265.157897623
Chemical Formula
C17H19N3
Synonyms
  • 2-(N-Benzylanilinomethyl)-2-imidazoline
  • 2-(N-Phenyl-N-benzylaminomethyl)imidazoline
  • 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine
  • Antazolina
  • Antazoline
  • Antazolinum

Pharmacology

Indication

Used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Antazoline is a histamine H1 receptor antagonist. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.

Mechanism of action

Antazoline binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Antazoline H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of QTc prolongation can be increased when Acebutolol is combined with Antazoline.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Antazoline.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Antazoline.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Antazoline.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Antazoline.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Antazoline.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Antazoline.
AmifampridineThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Amifampridine.
AmiodaroneThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Amiodarone.
AmisulprideThe risk or severity of QTc prolongation can be increased when Amisulpride is combined with Antazoline.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Antazoline phosphateVPR5FPH326154-68-7DUIGUKRYYAGJAF-UHFFFAOYSA-N
Antazoline sulfate6T74I0721224359-81-7UWOSJBSLQYMGDL-UHFFFAOYSA-N
International/Other Brands
Vasocon-a
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Albalon AAntazoline phosphate (.5 %) + Naphazoline hydrochloride (.05 %)LiquidOphthalmicAllergan1978-12-312017-07-26Canada flag
Cooper A.R.Antazoline phosphate (5 mg) + Naphazoline hydrochloride (.5 mg)Solution / dropsOphthalmicCoopervision, Inc.1996-08-141998-03-12Canada flag
Ophtrivin A Ophthalmic DpsAntazoline sulfate (.5 %) + Xylometazoline hydrochloride (.05 %)Solution / dropsOphthalmicCiba Vision1992-12-312000-11-08Canada flag
Refresh Eye Allergy ReliefAntazoline phosphate (0.51 %) + Naphazoline hydrochloride (0.051 %)SolutionOphthalmicAllergan2009-02-09Not applicableCanada flag
Steritears ArAntazoline phosphate (0.5 %) + Naphazoline hydrochloride (0.05 %)Solution / dropsOphthalmicLaboratoires Sterigen IncNot applicableNot applicableCanada flag
Vasocon A Eye DropsAntazoline phosphate (5 mg) + Naphazoline hydrochloride (.5 mg)Solution / dropsOphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-12-312005-03-01Canada flag
Vasocon A Oph SolnAntazoline phosphate (5 mg) + Naphazoline hydrochloride (.5 mg)Solution / dropsOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada flag
Zincfrin AAntazoline phosphate (0.5 %) + Naphazoline hydrochloride (0.05 %) + Zinc sulfate (0.125 %)Solution / dropsOphthalmicAlcon, Inc.1969-12-312009-04-24Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Nestabs ONEAntazoline (225 mg/1) + Calcium ascorbate dihydrate (18 mg/1) + Cholecalciferol (6.25 ug/1) + Cyanocobalamin (15 ug/1) + Folic acid (1 mg/1) + Iron (38 mg/1) + Magnesium oxide (15 mg/1) + Pyridoxine hydrochloride (30 mg/1) + Tocopherol (10 mg/1) + Zinc oxide (1 mg/1)Capsule, gelatin coatedOralWomens Choice Pharmaceuticals, Llc2017-07-20Not applicableUS flag

Categories

ATC Codes
R06AX05 — AntazolineR01AC04 — Antazoline
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylbenzamines
Alternative Parents
Dialkylarylamines / Benzylamines / Aniline and substituted anilines / Aralkylamines / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds
show 2 more
Substituents
2-imidazoline / Amidine / Amine / Aniline or substituted anilines / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzylamine / Carboximidamide / Carboxylic acid amidine
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amino compound, aromatic amine, imidazolines (CHEBI:84115)

Chemical Identifiers

UNII
DHA8014SS1
CAS number
91-75-8
InChI Key
REYFJDPCWQRWAA-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)
IUPAC Name
N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline
SMILES
C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1

References

Synthesis Reference

Miescher, K. and Klarer, W.; US. Patent 2,449,241; September 14,1948: assigned to Ciba Pharmaceutical Products, Inc.

General References
  1. Figus M, Fogagnolo P, Lazzeri S, Capizzi F, Romagnoli M, Canovetti A, Iester M, Ferreras A, Rossetti L, Nardi M: Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. Eur J Ophthalmol. 2010 Sep-Oct;20(5):811-8. [PubMed:20383847]
Human Metabolome Database
HMDB0015689
KEGG Drug
D07458
PubChem Compound
2200
PubChem Substance
99445269
ChemSpider
2115
BindingDB
76862
RxNav
865
ChEBI
84115
ChEMBL
CHEMBL1305
ZINC
ZINC000000057204
PharmGKB
PA165958418
Wikipedia
Antazoline
MSDS
Download (70.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentParoxysmal Atrial Fibrillation (PAF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidOphthalmic
Capsule, gelatin coatedOral
Solution / dropsOphthalmic
SolutionOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)227-229Miescher, K. and Klarer, W.; US. Patent 2,449,241; September 14,1948: assigned to Ciba Pharmaceutical Products, Inc.
water solubility663 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.114 mg/mLALOGPS
logP3.22ALOGPS
logP2.88ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)9.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area27.63 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity82.89 m3·mol-1ChemAxon
Polarizability30.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9699
Blood Brain Barrier+0.9578
Caco-2 permeable-0.5076
P-glycoprotein substrateSubstrate0.7167
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.59
Renal organic cation transporterInhibitor0.8403
CYP450 2C9 substrateNon-substrate0.798
CYP450 2D6 substrateSubstrate0.6581
CYP450 3A4 substrateNon-substrate0.6963
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.919
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9644
CYP450 3A4 inhibitorNon-inhibitor0.952
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.788
CarcinogenicityNon-carcinogens0.896
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5401
hERG inhibition (predictor II)Inhibitor0.5709
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-001i-9000000000-1eb3fa441bd25a0e41a3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Swiader MJ, Luszczki JJ, Wielosz M, Czuczwar SJ: Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. Pharmacol Rep. 2005 Jul-Aug;57(4):531-5. [PubMed:16129921]

Drug created on October 14, 2010 14:06 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates